Sign In to Your Account
Subscribers have complete access to the archive.
Sign In Not a Subscriber?Join Now
Features
THE TALENTED MS. HOLMES
From the moment Elizabeth Holmes arrived on the tech scene, around 2003, as a 19-year-old Stanford dropout with a world-changing idea, an epic ambition, and a Steve Jobs-ian aura, her rise was meteoric. By last October, her revolutionary blood-testing start-up, Theranos, was valued at some $9 billion, and she had been anointed the world's youngest self-made female billionaire. Then a Wall Street Journal reporter began looking at the science. In the wake of Theranos's stunning collapse, amid civil and criminal investigations and class-action lawsuits, NICK BILTON explains why Silicon Valley saw only what Holmes wanted it to see
Features
THE TALENTED MS. HOLMES
From the moment Elizabeth Holmes arrived on the tech scene, around 2003, as a 19-year-old Stanford dropout with a world-changing idea, an epic ambition, and a Steve Jobs-ian aura, her rise was meteoric. By last October, her revolutionary blood-testing start-up, Theranos, was valued at some $9 billion, and she had been anointed the world's youngest self-made female billionaire. Then a Wall Street Journal reporter began looking at the science. In the wake of Theranos's stunning collapse, amid civil and criminal investigations and class-action lawsuits, NICK BILTON explains why Silicon Valley saw only what Holmes wanted it to see
Subscribe to read this articleAlready a subscriber? Sign in